BioCryst Pharmaceuticals (BCRX) News Today

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) — Shares are trading higher after a flurry of analyst upgrades and price-target increases, alongside BioCryst’s announced acquisition of Astria Therapeutics (navenibart). Investors are reacting to both the strategic growth case and short‑term financial/transaction risks; watch the company’s conference call and financing details.

• Positive Sentiment: Cantor Fitzgerald raised its price target to $26 and kept an "overweight" rating — another bullish signal from sell‑side coverage. Article
• Positive Sentiment: TD Cowen initiated coverage with a "buy" rating and $30 target, adding momentum to the bullish analyst narrative. Article
• Positive Sentiment: Other firms (Needham to $20; JMP to $27) also lifted targets/ratings today, broadening analyst upside expectations. Needham JMP
• Positive Sentiment: Wedbush raised Q3 and FY2025 EPS estimates and maintains an Outperform rating, supporting expectations for improved near‑term profitability. Article
• Positive Sentiment: Strategic acquisition of Astria (navenibart) adds a Phase‑3, long‑acting injectable for HAE that could materially expand BioCryst’s product set and long‑term revenue runway; company expects accretion and continued non‑GAAP profitability. Press release
• Neutral Sentiment: BioCryst hosted an M&A call and posted transcripts/slides — useful for diligence on deal terms, timelines (close expected Q1 2026) and clinical milestones (Phase‑3 readout early 2027). Call transcript
• Negative Sentiment: Initial market reaction was negative: shares gapped down on the deal announcement while Astria stock jumped — investors cited dilution, near‑term financing and integration risk. Market reaction
• Negative Sentiment: Transaction includes a debt commitment (up to $550M from Blackstone) and stock consideration — increases leverage/dilution risk that could pressure the share price if financing terms or execution disappoint. Deal details

What to watch: the investor conference call/webcast, deal close and financing details, and navenibart’s Phase‑3 ALPHA‑ORBIT readout timeframe (early 2027). These will drive whether the market rewards the strategic rationale or focuses on near‑term dilution and execution risk.